Core Viewpoint - The stock price of Yuan Da Pharmaceutical (00512) has experienced a strong upward trend, achieving a four-day consecutive rise and over 20% increase within the week, driven by significant innovations in various fields [1]. Group 1: Innovations and Clinical Trials - The company has reached clinical endpoints in the Phase II trial of its innovative drug STC3141 for treating sepsis and has received acceptance for the Phase III clinical trial application of its radiopharmaceutical TLX591 for oncology [1][7]. - Yuan Da Pharmaceutical has a robust pipeline with 15 innovative products in the registration phase, covering multiple cancer types and offering integrated diagnostic and therapeutic solutions [3][5]. Group 2: Financial Performance - The nuclear medicine oncology segment is projected to generate approximately HKD 589 million in revenue for 2024, reflecting a year-on-year growth of nearly 177%, with the core product contributing nearly HKD 500 million [3]. - The company has seen its core product, Yttrium-90 microsphere injection, achieve over 140% year-on-year sales growth for two consecutive years [3]. Group 3: Strategic Developments - Yuan Da Pharmaceutical has established a comprehensive industrial layout, including R&D, production, sales, and regulatory qualifications, with a new radioactive drug R&D and production base in Chengdu expected to commence operations soon [6]. - The company is investing approximately HKD 3 billion in this facility, which aims to become a global hub for innovative nuclear medicine [6]. Group 4: Market Potential - The global market for sepsis treatment drugs is expected to grow from USD 12.54 billion in 2024 to USD 19.37 billion by 2032, with a compound annual growth rate of 5.58% [7]. - Yuan Da Pharmaceutical is positioned to fill a significant clinical gap in sepsis treatment with STC3141, which is anticipated to be a groundbreaking therapy [7]. Group 5: Eye Care Sector - The company has developed a comprehensive product system in the ophthalmology field, focusing on various eye diseases and has several innovative products in the pipeline [10][13]. - Yuan Da Pharmaceutical is recognized as a leader in the eye care sector, with a strong marketing network and a commitment to addressing unmet clinical needs [10][13].

证券代码：002422 证券简称：科伦药业 四川科伦药业股份有限公司投资者关系活动记录表 编号：0074 | | □分析师会议 □特定对象调研 | | --- | --- | | 投资者关系活 | □媒体采访 √业绩说明会 | | | □新闻发布会 □路演活动 | | 动类别 | □现场参观 | | | □其他：电话调研 | | 参与单位名称 | 本 次 业 绩 说 明 会 以 文 字 问 答 方 式 在 进 门 财 经 召 开 （ 网 址 ： | | 及人员姓名 | https://s.comein.cn/syfe7cqa）。 | | 时间 | 2025 年 5 月 6 日 15：00-17：00 | | 地点 | 线上 | | | 董事长刘革新先生；独立董事任世驰先生；副总经理兼财务总监赖德贵先 | | 上市公司接待 | 生；副总经理兼董事会秘书冯昊先生；销售负责人戈韬先生；科伦博泰首席 | | 人员姓名 | 财务官兼董事会秘书周泽剑先生；川宁生物副总经理兼董事会秘书顾祥先 | | | 生。 | | | 公司就投资者对经营现状、发展战略、研发进展等方面所提的问题进行了回复，主要内 | | | 容如下： | ...

Core Viewpoint - BeiGene has shown significant improvement in reducing losses, with a notable increase in revenue driven by the sales of its self-developed products [1][2][3] Financial Performance - In Q1 2025, BeiGene reported revenue of 8.048 billion yuan, a year-on-year increase of 50.2%, marking the second consecutive quarter with revenue exceeding 8 billion yuan [1][2] - The net profit attributable to shareholders was -94.503 million yuan, a substantial reduction from -1.908 billion yuan in the same period last year, achieving a loss reduction rate of 95.05% [1][2] - For the full year 2024, the company reported revenue of 27.21 billion yuan, up 56.2% year-on-year, with a net profit loss reduced to 4.98 billion yuan [2] Product Performance - BeiGene has three major self-developed products: BTK inhibitor Zebrutinib (brand name "百悦泽"), PD-1 monoclonal antibody Tislelizumab (brand name "百泽安"), and PARP inhibitor Pamiparib (brand name "百汇泽") [3][4] - In Q1 2025, Zebrutinib generated global sales of 5.692 billion yuan, a 63.7% increase, accounting for 70.73% of total revenue [4] - Tislelizumab's sales reached 1.245 billion yuan in Q1 2025, a 19.3% increase, primarily due to new indications being included in the national medical insurance catalog in China [4] Research and Development Investment - BeiGene has invested heavily in R&D, with cumulative expenditures reaching approximately 69.788 billion yuan over the past eight years [5] - R&D expenses have consistently increased from 2.017 billion yuan in 2017 to 14.14 billion yuan in 2024, reflecting the company's commitment to innovation [5]

目前，科创板创新药企业正迎来业绩加速兑现期，核心创新品种凭借差异化临床价值实现快速放量，多 款大单品销售收入呈现爆发式增长，市场渗透率持续提升；同时，企业商业化体系日趋成熟，自建销售 团队与渠道合作伙伴协同发力，叠加规模化生产带来的成本优化，盈利能力进入快速上升通道。 2024年是迪哲医药产品上市后的第一个完整会计年度，公司合计实现销售收入3.60亿元，同比增长 294.24%，交出了一份亮眼答卷。2024年11月，公司两款已上市产品舒沃哲和高瑞哲均成功纳入《国家 基本医疗保险、工伤保险和生育保险药品目录（2024年）》。迪哲医药董事长兼首席执行官张小林在本 场业绩说明会中表示，公司自主研发的高瑞哲是淋巴瘤领域全球首个且唯一针对外周T细胞淋巴瘤 （PTCL）的高选择性JAK1抑制剂。 5月8日，"科创热点行业周"迎来创新药行业专场，本次集体业绩说明会汇聚了18家科创板生物医药领军 企业，包括百利天恒、荣昌生物、迪哲医药、君实生物、复旦张江等代表性企业。与会企业高管围绕核 心技术突破、临床管线进展、商业化战略及全球合作等焦点话题，与广大投资者展开深度对话，展现中 国创新药企的科技硬实力与国际化视野。 ● 本报记 ...

Core Insights - The "Innovation Drug Industry Special Session" held on May 8 showcased 18 leading biotech companies from the STAR Market, emphasizing China's technological strength and international vision in the innovative drug sector [1] Group 1: Industry Overview - The STAR Market has attracted over 30 innovative drug companies focusing on treatments for cancer, HIV, hepatitis B, and hepatitis C, establishing itself as a major listing venue for global biotech firms outside the US and Hong Kong [1] - Innovative drug companies on the STAR Market have significantly increased R&D investments, leading to breakthroughs in key technology areas such as antibody-drug conjugates and bispecific antibodies [2] Group 2: Company Performance - In 2024, STAR Market innovative drug companies collectively achieved approximately 61.7 billion yuan in revenue, a 56% year-on-year increase, while narrowing net losses by 62% [3] - Dize Pharmaceutical reported a revenue of 360 million yuan in 2024, marking a 294.24% increase, driven by its innovative drug targeting peripheral T-cell lymphoma [3] - Junshi Biosciences achieved a revenue of 1.948 billion yuan in 2024, a 30% increase, with product sales reaching 1.640 billion yuan, significantly up from 1.191 billion yuan in 2023 [4]

智通财经APP讯，近日，港股科技创新型国际化医药企业远大医药(00512)连续发布多则利好消息，公司自主研发的全球创新药物STC3141在中国开展的用于 治疗脓毒症的II期临床研究成功达到临床终点，用于治疗前列腺癌的全球创新放射性核素偶联药物(RDC) TLX591 (177Lu- HuJ591)加入国际多中心III期临床 试验的申请已获得国家药监局受理。 公司多项创新药重磅研发进展已经获得了资本市场的高度认可——其股价已连续两日大涨，截至5月8日收报7.11港元，盘中一度触及7.24港元的高位，两日 总计涨幅近20%，较年内低点总计上涨近80%。 研发实力爆发：STC3141填补全球脓毒症治疗空白 根据公司5月6日公告，STC3141是由远大医药自主开发的、拥有全球知识产权的、具有全新作用机制的小分子化合物，其通过中和胞外组蛋白和中性粒细胞 诱捕网来逆转机体过度免疫反应造成的器官损伤，可用于多种重症适应症，如脓毒症和急性呼吸窘迫综合症(ARDS)等临床上死亡率高且缺乏特异性治疗药 物的疾病。该产品作用机制创新，相关研究结果已发布于顶级学术期刊《Nature Communications》和《Critical ...

Core Insights - The company Yipinhong has accelerated the development of its innovative gout drug AR882, which has entered global multi-center Phase III clinical trials, potentially filling a gap in the oral medication market for gout stone treatment [1][2][3] R&D Progress - AR882 has shown significant clinical progress, with the first patient enrolled in domestic Phase III trials on March 4 and completion of patient enrollment in the global REDUCE2 trial by March 6 [2][3] - The drug is designed to target URAT1, aiming to lower blood uric acid levels, dissolve gout stones, and treat chronic kidney disease, showcasing its potential to address unmet medical needs [2][3] Innovation Strategy - Yipinhong has established a robust R&D team of over 400 scientists and is committed to high investment in innovation, with a total of 71 ongoing projects [1][4][5] - The company is advancing 15 innovative drug projects, with AR882 and another drug, APH01727, currently in clinical trials, while others are in preclinical stages [5][6] Manufacturing Capabilities - The company has developed advanced manufacturing capabilities, including a digital production base compliant with EU and FDA standards, enhancing operational efficiency and safety [7][8] - The establishment of the Lianrui Intelligent Manufacturing Base in Nansha, which operates with minimal human intervention, reflects the company's commitment to modernizing its production processes [7] Market Positioning - Yipinhong focuses on the pediatric and chronic disease medication sectors, aiming to leverage its innovative capabilities to capture market opportunities in a competitive landscape [2][4] - The company is optimistic about the market potential for AR882, given the limited number of existing products for hyperuricemia and gout [3][4]

业绩高速增长，创新管线持续兑现：—— 奥赛康三季报点评 2024-11-11 创新驱动转型，变革中等待突破：——奥 赛康首次覆盖报告 2024-03-11 | | 买入 （维持） | | --- | --- | | 股价（2025年05月06日） | 17.7 元 | | 目标价格 | 22.36 元 | | 52 周最高价/最低价 | 20.36/9.03 元 | | 总股本/流通 A 股（万股） | 92,816/92,815 | | A 股市值（百万元） | 16,428 | | 国家/地区 | 中国 | | 行业 | 医药生物 | | 报告发布日期 | 2025 年 05 月 07 日 | | | 1 周 | 1 月 | 3 月 | 12 月 | | --- | --- | --- | --- | --- | | 绝对表现% | -7.14 | -5.25 | 30.24 | 56.36 | | 相对表现% | -8.03 | -3.88 | 31.13 | 52.24 | | 沪深 300% | 0.89 | -1.37 | -0.89 | 4.12 | 奥赛康 002755.SZ 公司研究 | 年 ...

Core Viewpoint - Heng Rui Medicine has shown significant growth and innovation in 2024, achieving record-high revenues and profits, while also advancing its internationalization strategy through successful licensing agreements and a planned IPO in Hong Kong [1][5][14]. Financial Performance - In 2024, Heng Rui Medicine reported revenue of 27.985 billion yuan, a year-on-year increase of 22.63%, and a net profit of 6.337 billion yuan, up 47.28% [5]. - For Q1 2025, the company achieved revenue of 7.206 billion yuan, reflecting a 20.14% year-on-year growth, with a net profit of 1.874 billion yuan, increasing by 36.9% [5]. Innovation and R&D - Heng Rui Medicine has invested a total of 46 billion yuan in R&D as of Q1 2025, with innovative drug sales accounting for over 50% of total revenue [4][5]. - The company has 19 approved new molecular entity drugs and over 90 innovative products in clinical development, with 400 clinical trials ongoing [6]. Licensing and Partnerships - In 2024, Heng Rui Medicine secured two major licensing agreements totaling nearly $2 billion, marking a significant expansion in its business development (BD) strategy [8][9]. - The company has completed 14 licensing agreements, with potential total transaction amounts reaching approximately $14 billion in the last three years [10][11]. Internationalization Strategy - Heng Rui Medicine is pursuing a dual strategy of "innovation + internationalization," with plans to issue H-shares in Hong Kong to fund R&D and commercialization efforts [13][14]. - The company aims to optimize its international cooperation model and explore partnerships with multinational pharmaceutical companies and innovative startups [12][15]. Leadership Changes - The appointment of Feng Ji as the new president is seen as a move to accelerate Heng Rui Medicine's innovation and internationalization strategies [16]. Future Outlook - With a robust pipeline of innovative drugs and an expanding international presence, Heng Rui Medicine is positioned to play a more significant role in the global pharmaceutical market [17].

Core Viewpoint - BeiGene (06160) reported strong financial performance in Q1 2025, achieving revenue of 8.048 billion RMB, a year-on-year increase of 50.2%, driven by robust sales of its core products, Brukinsa® (Zebutinib) and Tislelizumab [1][2]. Financial Performance - The company transitioned from a loss to profit in both operating profit and total profit for Q1 2025, with significant improvement in operating cash flow [1]. - The full-year revenue guidance for 2025 remains unchanged, projected between 35.2 billion RMB and 38.1 billion RMB, supported by the anticipated strong growth of Brukinsa® in the U.S. and other key markets [1]. Product Performance - Brukinsa® achieved global sales of 5.692 billion RMB, a 63.7% increase year-on-year, with U.S. sales reaching 4.041 billion RMB, up 61.9% [2][3]. - In Europe, Brukinsa® sales were 836 million RMB, a 75.4% increase, while in China, sales reached 590 million RMB, a 43.1% increase [3]. Research and Development - The company is advancing its pipeline in hematologic malignancies, with the BCL2 inhibitor Sonrotoclax entering registration clinical trials and ongoing trials for various indications [3][4]. - BGB-16673, a BTK degrader, is in Phase 3 trials, expected to address BTK resistance issues [5]. PD-1 Product Development - Tislelizumab (替雷利珠单抗) generated sales of 1.245 billion RMB, a 19.3% increase, benefiting from new indications and increased hospital access [6]. - The product is approved in 46 markets globally, with over 1.5 million patients treated, and has recently gained reimbursement in 11 new markets [6]. Future Outlook - The company plans to host an investor R&D day on June 26, focusing on its breast cancer pipeline and broader oncology product portfolio [8]. - BeiGene will adopt a new English name, BeOne Medicines Ltd., and relocate its registration to Switzerland, expected to be completed later this year [8].